Examples of such “precision medicine” include the BCR-ABL fusion gene in chronic myeloid leukemia (CML), PML-RARA fusions in acute promyelocytic leukemia (APL) and FLT3 mutations in acute myeloid leukemia (AML) [6–9]. This evidence concerns the gene ABL1 and acute promyelocytic leukemia.